Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents

Rohun U. Palekar, Andrew P. Jallouk, Gregory M. Lanza, Hua Pan, Samuel A. Wickline

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations

Abstract

As atherosclerosis remains one of the most prevalent causes of patient mortality, the ability to diagnose early signs of plaque rupture and thrombosis represents a significant clinical need. With recent advances in nanotechnology, it is now possible to image specific molecular processes noninvasively with MRI, using various types of nanoparticles as contrast agents. In the context of cardiovascular disease, it is possible to specifically deliver contrast agents to an epitope of interest for detecting vascular inflammatory processes, which serve as predecessors to atherosclerotic plaque development. Herein, we review various applications of nanotechnology in detecting atherosclerosis using MRI, with an emphasis on perfluorocarbon nanoparticles and fluorine imaging, along with theranostic prospects of nanotechnology in cardiovascular disease.

Original languageEnglish
Pages (from-to)1817-1832
Number of pages16
JournalNanomedicine
Volume10
Issue number11
DOIs
StatePublished - Jun 1 2015

Keywords

  • atherosclerosis
  • contrast agent
  • inflammation
  • theranostics
  • thrombosis

Fingerprint Dive into the research topics of 'Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents'. Together they form a unique fingerprint.

Cite this